Click it and Unblock the Notifications
Latest Updates
-
Women Car Rally Held In Gurugram On International Women’s Day, Boldsky Collaborates As Media Partner -
The Protein Gap In Women’s Diets: Gynaecologist Explains Why This Nutrient Matters From Puberty To Menopause -
Ralph Lauren Showcases ‘Jhumkas’ At Paris Fashion Week, Rekindling Debate On Credit For Indian Craft -
Viral Video: Pakistani Family Celebrates India’s T20 World Cup Victory With Cake, Sings Indian National Anthem -
Who Is Aditi Hundia? Viral Video Shows Ishan Kishan Celebrating India’s T20 World Cup Win With Girlfriend -
India Seal Historic T20 World Cup Win: Samson Tournament Star, Bumrah Match Hero, Dhoni Posts Special Message -
Horoscope for Today March 09, 2026 - Small Steps, Big Progress -
International Women’s Day 2026: 7 Powerful Ayurvedic Foods Every Woman Should Start Adding To Her Daily Diet -
What If WiFi, GPS Or Dishwashers Didn’t Exist? This Instagram Reel Credits Women Behind Everyday Inventions -
Women’s Day 2026: Why Creating Relaxation Spaces At Home Matters For Women Balancing Multiple Roles
SII Gets DCGI Nod To Manufacture Drug Substance, Test It For Developing Jab Against Omicron
India's drug regulator on Friday approved Serum Institute of India's proposal to manufacture a drug substance for the new Covid vaccine against the Omicron variant of coronavirus and carry out its testing and analysis, official sources said.
The move assumes significance in view of the country reporting a rise in daily new Covid-19 cases which include the Omicron variant.
Looking to undertake vaccine research against the Omicron variant, Director, Government and Regulatory Affairs at SII, Prakash Kumar Singh, recently had submitted an application to the Drugs Controller General of India (DCGI) for grant of permission to manufacture Drug substance of SARS-CoV-2 rS Protein (Covid-l9)Recombinant Spike Nanoparticle Vaccine (Omicron Variant) for examination test and analysis.
"As you are aware, the new coronavirus variant 'Omicron' has already been reported in more than 60 countries and is spreading very fast worldwide and in our country also. Our CEO Adar C Poonawalla is very much concerned about the protection of citizens of our country and world at large against coronavirus and its new variants, and we are relentlessly working on the development of SARS-CoV-2 rS Protein (Covid-19) Recombinant Spike Nanoparticle Vaccine (Omicron Variant)," an official source quoted Singh as having said in the application.
Development of this vaccine shall be another example of vaccine production strength of India in line with the clarion call of Prime Minister Narendra Modi "Making in India for the World" and shall further keep our country's flag flying high globally, he said.
After the review of their application, DCGI has given permission to manufacture SARS-CoV-2 rS Drug Substance (Omicron Variant) for Examination, Test and Analysis (for SIIPL Hadapsar site), an official source informed.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.
Continue with Google